Search research articles
Contact Us
Filters
Showing results (321-330 of 410) with videos related to
Page
of 41
Sort By:
The Lancet. Oncology
|
June 3, 2023
Health-related quality of life and pain outcomes with [<sup>177</sup>Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial
Karim Fizazi, Ken Herrmann, Bernd J Krause, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2007
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators
Tomasz M Beer, Christopher W Ryan, Peter M Venner, et al.
The Lancet. Oncology
|
November 13, 2012
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
Christopher J Logothetis, Ethan Basch, Arturo Molina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 10, 2008
Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor
Susan N Chi, Mary Ann Zimmerman, Xiaopan Yao, et al.
The New England Journal of Medicine
|
June 23, 2021
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Oliver Sartor, Johann de Bono, Kim N Chi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2018
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel
Susan Halabi, Sandipan Dutta, Catherine M Tangen, et al.
Neuro-Oncology
|
April 3, 2020
A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study
Nicole J Ullrich, Sanjay P Prabhu, Alyssa T Reddy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 29, 2021
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study
Kim N Chi, Simon Chowdhury, Anders Bjartell, et al.
Research Square
|
April 8, 2025
<i>SMARCB1</i> missense mutants disrupt SWI/SNF complex stability and remodeling activity
Garrett W Cooper, Benjamin P Lee, Won Jun Kim, et al.
Lancet (London, England)
|
September 18, 2024
<sup>177</sup>Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Michael J Morris, Daniel Castellano, Ken Herrmann, et al.
Page
of 41
Search research articles
Search
Showing results (321-330 of 410) with videos related to
Sort By:
Page
of 41
The Lancet. Oncology
|
June 3, 2023
Health-related quality of life and pain outcomes with [<sup>177</sup>Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial
Karim Fizazi, Ken Herrmann, Bernd J Krause, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2007
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators
Tomasz M Beer, Christopher W Ryan, Peter M Venner, et al.
The Lancet. Oncology
|
November 13, 2012
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
Christopher J Logothetis, Ethan Basch, Arturo Molina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 10, 2008
Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor
Susan N Chi, Mary Ann Zimmerman, Xiaopan Yao, et al.
The New England Journal of Medicine
|
June 23, 2021
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Oliver Sartor, Johann de Bono, Kim N Chi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2018
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel
Susan Halabi, Sandipan Dutta, Catherine M Tangen, et al.
Neuro-Oncology
|
April 3, 2020
A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study
Nicole J Ullrich, Sanjay P Prabhu, Alyssa T Reddy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 29, 2021
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study
Kim N Chi, Simon Chowdhury, Anders Bjartell, et al.
Research Square
|
April 8, 2025
<i>SMARCB1</i> missense mutants disrupt SWI/SNF complex stability and remodeling activity
Garrett W Cooper, Benjamin P Lee, Won Jun Kim, et al.
Lancet (London, England)
|
September 18, 2024
<sup>177</sup>Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Michael J Morris, Daniel Castellano, Ken Herrmann, et al.
Page
of 41